---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-25-000004"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2025-02-19T23:59:59+00:00"
generated_at: "2026-05-26T10:17:58.970334+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioMarin reports Q4 revenue $747M (+16%), full-year GAAP EPS $2.21, guides 2025 rev growth ~10%

## Summary
- Q4 total revenue $747M (+16% YoY); full-year $2.854B (+18%). GAAP diluted EPS $0.64 (Q4) and $2.21 (FY), up 154% YoY.
- Non-GAAP diluted EPS $0.92 (Q4) and $3.52 (FY), up 69% YoY. Non-GAAP operating margin 28.6% for FY, up 9.2 ppts.
- VOXZOGO revenue $208M in Q4 (+42%), $735M full-year (+56%); on track for >25% CAGR 2023-2027.
- FY 2025 guidance: total revenue growth ~10% at midpoint; non-GAAP diluted EPS growth ~22%; targeting $4B revenue by 2027.
- Pipeline: BMN 333 (CNP) first-in-human dosed, BMN 351 DMD data H2 2025; PALYNZIQ adolescent study data mid-2025.

## SEC filing metadata
- accession: 0001048477-25-000004
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2025-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847725000004/0001048477-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847725000004/bmrn-20250219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-25-000004
- JSON: https://secwatch.observer/filing/0001048477-25-000004.json
- Plain text: https://secwatch.observer/filing/0001048477-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.